



04-11-07

IFW

Dkt. No. 29248/18

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Erik Buntinx  
Appl. No. : 10/725,965  
Filed : December 2, 2003  
For : METHOD OF TREATING MENTAL DISORDERS USING  
OF D4 AND 5-HT2A ANTAGONISTS, INVERSE AGONISTS  
OR PARTIAL AGONISTS  
Art Unit : 1617  
Examiner : Umamaheswari Ramachandran  
Customer No.: 1912

**COMMUNICATION IN REPLY TO MARCH 13, 2007 OFFICE ACTION  
AND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

"Express Mail" mailing label No. EV 725834781 US  
Date of Deposit: April 10, 2007

I hereby certify that this paper or fee is being  
deposited with the United States Postal Service  
"Express Mail" service under 37 CFR 1.10 on the date  
indicated above and is addressed to the  
Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450.

Name: Alan D. Miller

Signature: [Signature]

Sir:

This Communication is submitted in response to the Office Action issued on March 13, 2007 in connection with the above-identified application. A reply is due by April 13, 2007. Accordingly, this Communication is being timely filed.

REMARKS

Claims 32-77 are pending in the subject application.

In the March 13, 2007 Office Action, the Examiner requested that applicant make an election of claims to pursue in the application together with an election of species.

In response to the restriction requirement, applicant hereby elects Group II, Claims 41-42, drawn to a pharmaceutical composition comprising (a) a compound having (i) a selective affinity for the Dopamine-4 (D4) receptor and (ii) a selective affinity for the 5-HT2A receptor, and (b) a selective serotonin re-uptake inhibitor, as a combined preparation for simultaneous, separate or sequential use for treating a disease or disorder with an underlying dysregulation of emotional functionality.

With respect to the species election, applicant elects the following:

(i) for disease or disorder - mood disorders;

(ii) for a compound having a selective affinity for the Dopamine-4 (D4) receptor and the 5-HT2A receptor - pipamperone; and

(iii) for the selective serotonin re-uptake inhibitor - citalopram.

Claims 41-42 encompass the elected invention.

Supplemental Information Disclosure Statement

This Supplemental Information Disclosure Statement is being filed to supplement the Information Disclosure Statement filed on August 9, 2005 in connection with the above-identified application.

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicant would like to direct the Examiner's attention to the twenty references that are listed on enclosed Forms PTO/SB/08A-B (2 pages). Copies of the nine non-patent literature documents are attached hereto. Non-English language Reference numbers 12-14 on the enclosed Forms were cited in an Official Communication issued in patent family member

Applicant: Erik Buntinx  
Appl'n. No.: 10/725,965  
Filed: December 2, 2003  
Page 3 of 3

European Patent Application EP 04 025 035.9; copies of relevant pages from the Official Communication are attached hereto (2 pages).


Applicant is submitting the subject Supplemental Information Disclosure Statement pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Accordingly, no fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement.

No fee is deemed necessary in connection with the submission of this reply. However, if any fee is required in connection with this submission or to maintain the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP  
Attorneys for Applicant  
90 Park Avenue  
New York, New York 10016  
(212) 336-8000

Dated: April 10, 2007  
New York, New York

By   
Alan D. Miller, Reg. No. 42,889